Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial

Completed

• Conditions: Hodgkin Lymphoma

• Registration Number: NCT05066555
• Lead Sponsor: Fondazione Italiana Linfomi - ETS

Brief Summary

Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in Italy part of Fondazione Italiana Linfomi.

Detailed Description

The FIL-Rouge design provides an ideal environment for validating the liquid biopsy in Classical Hodgkin lymphoma (cHL), since one arm of the study will utilize a PET/CT-adapted strategy (Positron Emission Tomography/Computed Tomography)for treatment, while the second arm will be devoid of any PET/CT-adaptation of therapy. Also, estimating prospectively differences in residual disease between the two study arms of the FIL-Rouge will provide an important biologic tool to validate the concept of dose-intensification within the ABVD therapeutic platform.

This study aims at the prospective validation of the concept of the liquid biopsy as a biomarker for disease response assessment in cHL. The patients enrolled in the FIL-Rouge clinical trial at the centers participating in this study and consenting to the biological study FIL-RougeBIO will be considered for this study. After providing written informed consent, relevant patients will be evaluated for detecting cancer gene mutations in ctDNA (Circulating Tumor DNA) for measuring residual disease. All clinical data useful for data analyses of this study will derive from the FIL-Rouge clinical trial.

Given the non-interventional design of the study, project participants will not have immediate potential benefits.The enrollment in FIL-RougeBIO will parallel the original protocol until reaching the 500 programmed patients. The results of this study could benefit future patients with the same condition.

Study Timeline

• Study Start: 2020-04-08
• Study First Submitted: 2021-09-06
• Study First Submitted QC: 2021-09-24
• Study First Posted: 2021-10-04
• Primary Completion: 2021-11-02
• Study Completion: 2024-11-03
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-30
• Last Update Posted: 2024-12-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

FIL ROUGE INCLUSION CRITERIA

• Histologically confirmed classical HL

• Previously untreated disease

• Age 18-60 years

• Ann Arbor stage IIB with extranodal involvement and/or bulk, III and IV

• At least one target PET-avid bidimensionally assessable lesion

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2

• Adequate organ and marrow function as defined below:

  • Absolute neutrophil count >1,0 x109/L, platelets >75 x109/L
  • Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome
  • Aspartate Transaminase and Alanine Transaminase (AST/ALT) <3 X institutional Upper Limits of Normality (ULN)
  • Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2

• Females of childbearing must have a negative pregnancy test under medical supervision even if patients had been using effective contraception

• Life expectancy > 6 months

• Able to adhere to the study visit schedule and other protocol requirements

• Signed (or legally acceptable representatives must sign) informed consent indicating that patients understand the purpose of and procedures required for the study and are willing to participate in the study.

• Access to PET-CT (Positron Emission Tomography/Computed Tomography) scans facilities qualified by FIL

Read More

Exclusion Criteria

FIL ROUGE EXCLUSION CRITERIA

• Nodular Lymphocyte Predominant HL
• Ann Arbor stage IIB without extranodal involvement and/or mediastinal bulky
• Prior chemotherapy or radiation therapy
• Pregnant or lactating females
• Known hypertension, cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or left ventricular ejection fraction (LVEF) ≤50% at echocardiography.
• Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)
• Diffusion lung capacity for CO (DLCO)and/or Forced expiratory volume in the 1st second (FEV1) tests <50% of predicted not due to mediastinal compression or parenchymal lymphoma
• Known cerebral or meningeal disease (HL or any other etiology)
• Prior history of malignancies unless the patient has been free of the disease for five years. Exceptions include the following: basal cells carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast and prostate cancer with the TNM stage of T1a or T1b
• Uncontrolled infectious disease
• Human immunodeficiency virus (HIV) positivity or active infectious A, B or C hepatitis. HBsAg-negative patients with anti-HBc (Hepatitis B core) antibody and can be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that antiviral treatment with nucleos(t)ide analogs is provided (Lamivudine)
• Uncompensated diabetes
• Refusal of adequate contraception
• Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete Response Rate (CRR)	The endpoint will be assessed from the beginning of the study up to 76 months	Complete Response Rate (CRR) is defined as the proportion of patients achieving a Complete Remission (CR) at the end of treatment;

Secondary Outcome Measures

Name	Time	Method
Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (Positron Emission Tomography/Computed Tomography)	The endpoint will be assessed from the beginning of the study up to 76 months	Diagnostic accuracy of Circulating tumor DNA (ctDNA) analysis versus interim PET/CT (sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios accuracy); The endpoint will be evaluated through specific timepoints.
Progression Free Survival (PFS) with at least three years of follow up	The endpoint will be assessed from the beginning of the study up to 76 months	PFS is defined as the interval elapsing from randomization until lymphoma progression/relapse or death as a result of any cause.

Trial Locations

Locations (13)

Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico; 🇮🇹 Avellino, Italy

IRCCS Istituto Tumori Giovanni Paolo II - U.O.C Ematologia; 🇮🇹 Bari, Italy

ASST Spedali Civili di Brescia - Ematologia; 🇮🇹 Brescia, Italy

Ospedale degli Infermi di Rimini - U.O. di Ematologia; 🇮🇹 Rimini, Italy

ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia; 🇮🇹 Milano, Italy

Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - UOC Ematologia Oncologica; 🇮🇹 Napoli, Italy

Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia; 🇮🇹 Pagani, Italy

Istituto Clinico Humanitas - U.O. Ematologia; 🇮🇹 Rozzano, Italy

A.O.U. Citta della Salute e della Scienza di Torino - S.C.Ematologia; 🇮🇹 Torino, Italy

A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia; 🇮🇹 Palermo, Italy

IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia; 🇮🇹 Pavia, Italy

P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi; 🇮🇹 Pescara, Italy

Ospedale S. Maria della Misericordia - Ematologia; 🇮🇹 Perugia, Italy